Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara, Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Abstract
Purpose: To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Methods: Patients with locally advanced or metastatic HER2-low (cohort 1, immunohistochemistry 2+/in situ hybridization-negative; cohort 2, immunohistochemistry 1+) gastric/GEJ adenocarcinoma treated with at least two prior regimens, including fluoropyrimidine and platinum, but anti-HER2 therapy naive, received T-DXd 6.4 mg/kg intravenously once every 3 weeks. The primary end point was confirmed objective response rate by independent central review.
Results: Among 21 patients enrolled in cohort 1 and 24 enrolled in cohort 2, 19 and 21 patients, respectively, had central HER2 confirmation, received T-DXd, and had measurable tumors at baseline. The confirmed objective response rate was 26.3% (95% CI, 9.1 to 51.2) from five partial responses in cohort 1 and 9.5% (95% CI, 1.2 to 30.4) from two partial responses in cohort 2. Thirteen patients (68.4%) in cohort 1 and 12 (60.0%) in cohort 2 experienced reduced tumor size. The median overall survival was 7.8 months (95% CI, 4.7 to nonevaluable) in cohort 1 and 8.5 months (95% CI, 4.3 to 10.9) in cohort 2; the median progression-free survival was 4.4 months (95% CI, 2.7 to 7.1) and 2.8 months (95% CI, 1.5 to 4.3), respectively. The most common grade ≥ 3 treatment-emergent adverse events in cohorts 1 and 2 were anemia (30.0% and 29.2%), decreased neutrophil count (25.0% and 29.2%), and decreased appetite (20.0% and 20.8%). Drug-related interstitial lung disease/pneumonitis occurred in one patient in each cohort (grade 1 or 2). No drug-related deaths occurred.
Conclusion: This study provides preliminary evidence that T-DXd has clinical activity in patients with heavily pretreated HER2-low gastric/GEJ adenocarcinoma.
Trial registration: ClinicalTrials.gov NCT03329690.
Conflict of interest statement
Kohei Shitara
Honoraria: Bristol Myers Squibb, Takeda, Janssen
Consulting or Advisory Role: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Boehringer Ingelheim, Amgen, Astellas Pharma, Guardant Health Japan
Research Funding: MSD (Inst), Daiichi Sankyo (Inst), Taiho Pharmaceutical (Inst), Chugai Pharma (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), Eisai (Inst), Amgen (Inst)
No other potential conflicts of interest were reported.
Figures
![FIG 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g001.jpg)
![FIG 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g004.jpg)
![FIG 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g005.jpg)
![FIG A1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g007.jpg)
![FIG A2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g008.jpg)
![FIG A3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9901967/bin/jco-41-816-g009.jpg)
References
- Iqbal N, Iqbal N: Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int 2014:852748, 2014
- Van Cutsem E, Bang YJ, Feng-Yi F, et al. : HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476-484, 2015
- Aoki M, Iwasa S, Boku N: Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: A clinical perspective. Gastric Cancer 24:567-576, 2021
- Pietrantonio F, Caporale M, Morano F, et al. : HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer 139:2859-2864, 2016
- Bang YJ, Van Cutsem E, Feyereislova A, et al. : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
- Janjigian YY, Kawazoe A, Yanez PE, et al. : Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol 39, 2021. (suppl 15; 4013)
- Ogitani Y, Aida T, Hagihara K, et al. : DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097-5108, 2016
- Nakada T, Sugihara K, Jikoh T, et al. : The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo) 67:173-185, 2019
- Shitara K, Bang YJ, Iwasa S, et al. : Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419-2430, 2020
- Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing information. Basking Ridge, NJ, Daiichi Sankyo, 2022
- Ogitani Y, Hagihara K, Oitate M, et al. : Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107:1039-1046, 2016
- Takegawa N, Tsurutani J, Kawakami H, et al. : [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer 145:3414-3424, 2019
- Doi T, Shitara K, Naito Y, et al. : Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study. Lancet Oncol 18:1512-1522, 2017
- Modi S, Park H, Murthy RK, et al. : Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study. J Clin Oncol 38:1887-1896, 2020
- Modi S, Jacot W, Yamashita T, et al. : Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9-20, 2022
- Shitara K, Iwata H, Takahashi S, et al. : Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study. Lancet Oncol 20:827-836, 2019
- Makiyama A, Sukawa Y, Kashiwada T, et al. : Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol 38:1919-1927, 2020
- National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer, Version 4.2021. Plymouth Meeting, PA, National Comprehensive Cancer Network, 2021
- National Comprehensive Cancer Network : Esophageal and Esophagogstric Junctions Cancers. version 4.2021. Plymouth Meeting, PA, National Comprehensive Cancer Network, 2021
- Japanese Gastric Cancer Association : Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 17:1-19, 2020
- Shitara K, Doi T, Dvorkin M, et al. : Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437-1448, 2018
- Skidmore L, Sakamuri S, Knudsen NA, et al. : ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers. Mol Cancer Ther 19:1833-1843, 2020
- Banerji U, van Herpen CML, Saura C, et al. : Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20:1124-1135, 2019
- Peng Z, Liu T, Wei J, et al. : A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. J Clin Oncol 38, 2020. (suppl 15; abstr 4560)
- Van Cutsem E, Di Bartolomeo M, Smyth E, et al. : Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Ann Oncol 32, 2021. (suppl 5; abstr LBA55)
Source: PubMed